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Weevaluatedtheassociationofepidermalgrowthfactorreceptor(EGFR)142285G>A(R521K)andestrogenreceptoralpha(ESR1)
2014G>A(T594T)singlenucleotidepolymorphismswithbreastcancerriskandprognosisinTunisianpatients.EGFR142285G>A
and ESR1 2014G>A were genotyped in a sample of 148 Tunisian breast cancer patients and 303 controls using PCR-RFLP method.
Immunohistochemitsry was used to evaluate the expression levels of EGFR, HER2, ESR1, progesterone receptor and BCL2 in
tumors. We found no evidence for an association between EGFR R521K polymorphism and breast cancer risk. However, we
found that the homozygous GG (Arg) genotype was more prevalent in patients with lymph node metastasis (P = .03) and high
grade tumors (P = .011). The ESR1 2014G allele showed signiﬁcant association with breast cancer risk (P = .025). The GG
genotype was associated with HER2 overexpression and this association withstood univariate and multivariate analyses (P = .009;
P = .021, resp.). These data suggest that the R521K might be a prognostic factor, because it correlates with both tumor grade and
nodule status. The higher expression of HER2 in ESR1 T594T GG patients suggests the possibility that ESR1 gene polymorphisms
accompanied by HER2 expression might inﬂuence the pathogenesis of breast cancers.
Copyright © 2009 Imen Kallel et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The epidermal growth factor receptor (EGFR, MIM:
131550), also known as HER-1 or ErbB-1, is the prototype
member of the type I receptor tyrosine kinase (TK) family.
It is a transmembrane protein with intrinsic tyrosine kinase
activity,whoseactivationleadstodownstreameﬀectsin gene
expression, cellular proliferation, inhibition of apoptosis,
and angiogenesis [1]. Exons 1–14 code for the extracellular
domain, exon 15 encodes the transmembrane region, and
exons 16–20 code for the intracellular tail. EGFR belongs
to the ErbB family of TK receptors, whose other members
include ErbB2 (HER2/neu, MIM: 164870), ErbB3 (HER3,
MIM: 190151), and ErbB4 (HER4, MIM: 600543) [2].
A polymorphic variant in the EGFR gene arising from
a single nucleotide substitution (142285G>A) leading to an
Arginine (R)/Lysine (K) substitution in codon 521 in the
extracellular subdomain IV of the EGFR gene (rs11543848,
also known as HER-1 R497K) has been identiﬁed [3].
Compared with the “wild-type” HER-1 142285G (521R)
allele, that the 142285A (521K) variant has attenuated
function in ligand binding, growth stimulation, tyrosine
kinaseactivation,andinductionoftheproto-oncogenesmyc,
fos,a n djun [4].
Among the steroid receptors, estrogen receptor alpha
(ERα or ESR1, MIM: 133430) and the ER-regulated pro-
gesterone receptor (PGR, MIM: 607311) are of special
interest because of their elevated protein levels in some
premalignant and malignant breast cells [5]. ERs belong
to a family of transcription factors, the nuclear receptor
superfamily, responsible for mediating the eﬀects of several
hormone families including sex steroids on development,
reproduction, proliferation, cellular homeostasis and gene
expression [6]. There are two isoforms of ER, ESR1 and2 Journal of Biomedicine and Biotechnology
Table 1: Position of SNP and enzyme and primers used in this study.
Genes∗ Variation rs code∗∗ Enzyme Primer sequences (5 -3 )
EGFR A/G rs11543848 MvaI F 5 -TGCTGTGACCCACTCTGTCT-3
 
(rs2227983) R 5 -CCAGAAGGTTGCACTTGTCC- 3
 
ESR1 A/G rs2228480 BtgI F 5 -GAGGAGACGGACCAAAGCCAC-3
 
R5  -GCCATTGGTGTTGGATGCATGC-3
 
∗gene names according to gene database in NCBI: http://www.ncbi.nlm.nih.gov/gene.
∗∗rs code in dbSNP http://www.dbsnp.org/.
ESR2 (MIM: 601663), showing 47% sequence identity in
the human genome. The ESR1 gene (ERα)l o c a t e do n
chromosome 6q25–27 has eight exons and spans more than
140 kilobases. The ESR2 gene (ERβ) located on chromosome
14q23-24 has also eight exons spanning approximately 40
kilobases.
The overexpression of ERs in breast tumour tissues has
been demonstrated to be a signiﬁcant prognostic factor
that correlates with higher survival rates and lower risk of
relapse [7]. Inherited variants of the estrogen receptor gene
have been observed to occur at increased rates in breast
cancer [8]. One of the most studied polymorphism is the
codingsynonymousvariantatcodon594(rs2228480)within
the last exon of the gene. This variant is thought to play
a role in distinguishing between the receptor agonist or
antagonists binding to the receptor molecule [9] and has
beensuggested,althoughinconsistently,tobeassociatedwith
risk of breast cancer [10] and more recently of thyroid cancer
[11].
In the present study, we analyzed the two above men-
tioned polymorphisms (EGFR142285G>A; ESR12014G>A)
in 148 breast cancer patients and 303 healthy individuals and
investigated their association with breast cancer in order to
evaluate their potential as prognostic/predictive factors.
2.MaterialsandMethods
2.1. Population Samples. The studied population comprised
148 Tunisian women with pathologically proven breast
cancer selected from the register of Sfax University Hospital
Habib Bourguiba between the years 2001 and 2006. Only
patients that have complete clinical records and frozen
tumor samples were included in the study. The average age
was 49.9 ± 11.4 (range 17–78 years). One hundred twenty
nine patients had invasive ductal carcinoma, 6 patients had
invasive lobular carcinoma and 10 patients had medullar
or tubular cancers. Histological grade was not available
for lobular carcinomas since tubule formation is not a
characteristic of the tumour.
The protein expression levels of EGFR, HER2, ESR1,
PGR, and BCL2 (MIM: 151430) was assessed using
immunohistochemistry on frozen tissue. Their primary anti-
body, (respectively: DM267/ACRIS, BM5084/ACRIS, clone
1D5/DAKO, clone PgR636/DAKO, clone 124/DAKO) were
incubated during 30 minutes at room temperature, A
biotin-labeled secondary antibody (goat antirabbit, DAKO,
1:500) was used for 15 minutes at room temperature. Then
the avidin-biotin-HRP complex as directed by DAKO was
applicated for 15 minutes, ﬁnally, the immunoprecipitate
was visualised by treating with diaminobenzidine tetrahy-
drochloride (DAB) (DAKO) for 30 minutes. The sections
were counterstaining with haematoxylin. Immunostaining
was considered positive if more than 5% of tumour cells
were stained and scored on the basis of the approxi-
mate percentage of positive tumours cells and the relative
immunostaining intensity [12].
Other variables such as tumour size (in cm), Scarﬀ-
Bloom-Richardson (SBR) grade and nodal status were also
evaluated.Tumourgradeswereasfollows:well-diﬀerentiated
collectively referred to as SBR grade I (n = 9), grade II
(n = 76), and grade III (n = 44) disease. The nodal
status was known for 144 patients; 52 (36.1%) had no nodal
involvement, lymph node invasion was detectable in 92 cases
(63.8%).51hadonetothreenodesinvolvedand41hadmore
than three nodes involved.
The control group comprised 303 individuals with no
personal or familial history of cancer. The average age of
controls was 61.7 ± 9.7 (range 17–87) years.
2.2. DNA Extraction and Genotyping. DNA was extracted
from frozen breast cancer tumours and peripheral blood
samples of patients and controls using DNA puriﬁcation kit
(Promega,USA).DNAwasalsoextractedfrombloodofsixty
patients, for whom blood samples were available.
EGFR 142285G>A was genotyped by a polymerase chain
reaction-restriction fragment length polymorphism (PCR-
RFLP) method [3]( Table 1). The PCR product (155bp)
was digested by MvaI restriction enzyme (Fermentas, LIFE
SCIENCES) at 37◦C overnight. This restriction enzyme
recognizes the sequence CC/WGG. The G-allele carrying
PCR product is cleaved twice by the enzyme giving rise to
three fragments (38, 50 and 67bp), whereas the A allele
is cleaved only once (38 and 117bp). Digestion products
were separated by electrophoresis on 4% Nusieve ethidium
bromide-stained agarose gels and visualized under UV light.
ESR1 2014G>A was analysed using PCR-RFLP [10]
(Table 1). The PCR products of 227 (bp) were then digested
with BtgI (C/CRYGG) (New England Biolabs, Inc., USA)
overnight at 37◦C. The sizes of the restriction fragments
of PCR product were 227bp for the wild type homozygote
(AA), 129 and 98bp for the GG genotype and 227, 129 and
98bp for the heterozygote (AG).
Genotypes of tumour and blood samples from sixty
patients were found to be identical. In data analysis, we
considered only genotypes from tumours assuming them to
be identical to blood DNA genotypes for all patients.Journal of Biomedicine and Biotechnology 3
Table 2: Allelic and genotype distribution frequencies of R521K and T594T polymorphism in the patients and the control groups.
Polymorphism Genotypes Alleles (%)
AA AG GG A G
EGFR R521K
Cases (n = 148) 12 46 90 70 (23.6) 226 (76.3)
Controls (n = 303) 26 103 174 155 (25.6) 451 (74.4)
AA versus GG AA versus AG AA versus (AG + GG) A versus G
Odds ratio 1.12 0.97 1.06 1.110
(95%CI) [0.54–2.17] [0.45–2.08] [0.52–2.17] [0.80–1.53]
Chi-square (P-value) .09 (.76) .01 (.93) .03 (.86) .40 (.52)
ESR1 T594T
Cases (n = 142) 5 36 101 46 (16.3) 236 (83.7)
Controls (n = 240) 17 76 147 110 (22.9) 370 (77.1)
AA versus GG AA versus AG (AG + AA) versus GG A versus G
Odds ratio 2.33 1.61 1.56 1.54
(95%CI) [0.83–6.53] [0.55–4.71] [1–2.44] [1.05–2.25]
Chi-square (P-value) 2.75 (.10) .77 (.38) 3.812 (.05) 4.96 (.025)
2.3. Statistical Analysis. Diﬀerences in allele and genotype
frequencies were evaluated by the Chi-square or Fisher exact
test. We used the programs Hwe, Conting and Relrisk
from linkage utility programs to test for Hardy-Weinberg
equilibrium in control and to calculate χ2 tests for genotypic
and allelic association and odds ratios (OR) with their 95%
conﬁdence intervals (http://linkage.rockefeller.edu/).
Association between each of the SNP and clinicopatho-
logical parameters was assessed using chi-square test. To
study correlation between clinical parameters and genotypes
of EGFR and ESR1 polymorphisms in multivariate mode
we used binary logistic regression with each parameter
as dependent variable and genotypes of the two studied
SNP together with other clinical parameters as independent
variables. Statistical signiﬁcance for all tests was declared
when P-values are <.05.
3. Results
3.1. Association of Polymorphisms with Cancer Risk. Allelic
and genotype frequencies of the two studied polymorphisms
in patients (DNA from blood samples) and controls are
given in Table 2. Genotype frequencies for rs11543848 and
rs2228480 in controls agreed with frequencies expected
under the Hardy-Weinberg equilibrium.
Regarding EGFR R521K, genotype and allele frequencies
were very similar between patients and controls. In both
groups, about 60% of individuals were homozygous R/R,
32% were R/K heterozygotes and the remaining 8% carried
the K/K genotype.
Concerning the ESR1 codon 594 SNP, we found the
frequency of the G allele to be signiﬁcantly higher in
patients than in controls (P = .025). The same trend, albeit
barely signiﬁcant, was observed for the GG genotype (P =
.05) (Table 2). The ESR1 594 SNP provides 71% empirical
power for association at 5% signiﬁcance level calculated as
described in Maalej et al. [13].
3.2. Association between SNP and Clinical Parameters in
Patients. Table 3 shows a signiﬁcant association between
EGFR R521K genotypes and SBR grade (P = .011) and
Lymph-node status (P = .03). Genotypes RK and KK were
more frequent in patients with positive nodal status and KK
homozygotes were more prevalent in SBR grade III than in
other tumours. In logistic regression analysis, the association
between SBR grade and EGFR R521K genotype was even
higher after adjustment for other clinical parameters and
for the ESR1 2014G>Ap o l y m o r p h i s m( P = .008). The RR
genotype seems to be associated with a good prognosis.
No association was found between ESR1 T594T and any
of the clinical parameters in this study, except the strong
association revealed with HER2 status both in univariate
(P = .009) and in multivariate analysis using logistic
regression with HER2 status as dependent variable adjusting
for other clinical variables (P = .021). However, multivariate
analysisofnodalstatusdetectedasigniﬁcantassociationwith
ESR1 T594T genotype (P = .041). It should be noted that
genotype GG was more prevalent in tumours with positive
HER2 compared to those with negative HER2 (82.4% versus
60%, resp.).
4. Discussion
Cancer is a complex disease where genetic mutations,
deletions, rearrangement, or deletions as well as gene
polymorphisms of other genes may aﬀect not only cancer
development but also cancer progression and as a result
could inﬂuence cancer phenotypes [14]. In this study we
investigated two polymorphisms within the EGFR and ESR1
genes that are known to play a key role in breast cancer onset
and progression. EGFR is frequently overexpressed in a wide
variety of solid tumors and is a target for cancer drugs [15].
The possibility that diﬀerent genetic polymorphisms in the
EGFR gene may regulate, at least in part, EGFR expression
and/or activity, is an attractive hypothesis that may help4 Journal of Biomedicine and Biotechnology
Table 3: Association between EGFR and ESR1 genotype with EGFR, HER2, ER, PR, and BCL2 protein expression and clinical parameters.
Parameter Genotype counts Genotype counts
EGFR R521K ESR1 T594T
AA AG GG Chi-square AA AG GG Chi-square
P-value P-value
Tumour size
≤2cm 2 5 17 1.172 0 6 17 1.077
>2cm 9 37 70 .557 52 97 8 .584
Lymph-node
Negative 6 9 37 7.022 3 16 31 3.629
P o s i t i v e 63 55 1 . 0 3 0 21 96 8 .163
Tumour grade
SBR I/II 9 31 45 9.103 3 18 60 3.080
SBR III 1 8 35 .011 0 14 28 .214
Estrogen receptor 1
Negative – 5 12 26 1.035 2 8 32 1.640
Positive + 6 29 54 .596 2 24 59 .440
Progesterone receptor
Negative − 4 12 39 3.575 2 12 41 .717
Positive + 7 30 46 .167 32 25 3 .699
BCL2-protein
Negative – 1 7 18 1.502 1 7 18 .6
Positive + 7 16 35 .472 11 34 4 .741
HER2-protein
Negative – 3 13 24 .581 0 16 24 9.428
Positive + 6 15 36 .748 284 7 .009
EGFR-protein
Negative – 7 12 32 3.112 2 13 36 1.631
Positive + 1 11 21 .211 072 6 .442
to identify patients whose tumours are likely to respond to
EGFR-targeted therapies or radiotherapy [16].
Among the most interesting polymorphisms, the EGFR
variantR521Khasbeenpreviouslydescribedtobeassociated
with cancer severity in other EGFR expressing tumours, such
as gliomas and lung cancer [17]. Patients with rectal cancer
carrying the R allele tended to have a higher risk of local
recurrence [3, 18].
In our population-based case-control study, we found no
evidenceforanassociationbetweenR521Kandbreastcancer
risk. The frequency of the K allele in controls and patients
wasverysimilar(25.5%versus23.6%).AccordingtotheSNP
database, the frequency of the K allele in our population
is similar to that in Europeans (25%). In comparison,
its reported frequency in African-American, Subsaharan-
African, and Asians is 10.9%, 16% and 45.1%, respectively.
We found a signiﬁcant correlation between R521K
genotypedistributionandSBRgradesIandII(P = .011)and
lymph node metastasis (P = .03). The association between
EGFR variant R521K and lymph node metastasis deserves
further consideration in future studies as a clinical indicator
during presurgical evaluation; in fact, various studies of
lymph node metastasis have considered factors such as
intrinsic genetic factors involving cell mobility, vascular
invasion and angiogenesis [19, 20].
The R521K EGFR genotype correlates with a decrease
in EGFR phosphorylation, decreased invasion, lower nodal
involvement, reduced subsequent metastasis, and longer
disease-free and overall survival in stage II/III colorectal
carcinoma patients who have received curative surgery [18].
Zhang et al. [3] reported that EGFR polymorphism R521K
was negatively associated with pelvic recurrence in patients
with rectal cancer treated with chemoradiation.
The second SNP that we investigate here is the syn-
onymous codon T594T A/G transition in the ESR1 gene.
Estrogen receptor alpha gene (ESR1) has been implicated in
the initiation and development of breast cancer. Since it is an
important mediator of the hormonal response in estrogen-
sensitive tissues, ESR1 polymorphism was postulated to be
potential risk factor of breast cancer [21]. We found here
a signiﬁcant association of G variant with breast cancer
risk. This result is in agreement with reports in European
populations [8] but this association was not reported in the
Turkish population [10].
The expression of HER2 was more pronounced in the
presence of the ESR1 GG genotype. The cytoplasmic over-
expression of HER2 in human breast cancer is considered
to be a poor prognostic factor [22]. It was reported that
the HER2 gene harbours an estrogen-responsive element
ERE [23] in its regulatory region. Since the polymorphismJournal of Biomedicine and Biotechnology 5
ESR1 codon 594 was hypothesized to be associated with
altered receptor expression and function [24, 25] this might
explain its relation to HER2 expression level. The increased
expression of ErbB-2 and the EGFR external domain in the
presence of the GG genotype might provide an increased risk
for breast cancer. Polymorphisms of the ESR1 genes have
beensuggestedtobeassociatedwiththeoccurrenceofseveral
disorders [26, 27], including breast cancer [28, 29].
In multivariate analysis a signiﬁcant association was
f o u n db e t w e e nE S R 1c o d o n5 9 4a n dl y m p hn o d es t a t u s
in Tunisian population. A similar result was reported in
Taiwanese population [20]. This suggests that this marker
would be a good predictor of nodal status prior to surgical
intervention and thereby provides an indicator for deciding
whether chemotherapy should be given or not.
5. Conclusion
In summary, in a Tunisian breast cancer patient population,
a signiﬁcant association was found between SNP R521K of
EGFR (rs2227983) and SBR grade as well as with Lymph-
node status, suggesting that this polymorphism might be
clinically important in prognosis. The association of ESR1
polymorphismswithbreastcancerriskandHER2expression
but not with other clinical parameters might reﬂect that
it plays a role in the pathogenic processes resulting in the
development of breast cancer. With multivariate analysis
a correlation between Lymph node metastasis and GG
genotype of ESR1 2014G>A (T594T) was found. Validation
andfunctionalstudiesareneeded toassessthesigniﬁcanceof
these associations in clinical practice.
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